Dynamic changes in vasohibin and nitric oxide signaling following surgical resection of head and neck squamous cell carcinoma
Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced an...
Saved in:
Published in | World journal of surgical oncology Vol. 23; no. 1; pp. 221 - 11 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
07.06.2025
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection.
We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting.
Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL
vs. 2425 ± 1493 pg·mL
, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds.
This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. |
---|---|
AbstractList | Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection.BACKGROUNDAngiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection.We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting.METHODSWe prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting.Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL-1 vs. 2425 ± 1493 pg·mL-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds.RESULTSPatients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL-1 vs. 2425 ± 1493 pg·mL-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds.This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control.CONCLUSIONSThis study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL vs. 2425 ± 1493 pg·mL , p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. Abstract Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. Methods We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Results Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL−1 vs. 2425 ± 1493 pg·mL−1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. Conclusions This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide synthase (iNOS), implicated in its regulation and potential prognostic value in oncology. However, their roles in modulating surgery-induced angiogenesis in head and neck squamous cell carcinoma (HNSCC) remain unclear. Therefore, the objective of the study was to assess the dynamic changes in VASH, NO, and iNOS levels in HNSCC patients undergoing surgical resection. Methods We prospectively enrolled patients with histology-proven HNSCC who underwent surgical resection of primary tumors at the medical center between May and November 2021. Non-cancer controls were recruited to compare baseline biomarker levels with those of HNSCC patients. We measured preoperative and postoperative levels of VASH1 and VASH2 in plasma and leukocytes using enzyme-linked immunosorbent assays and Western blotting, NO using nitrate/nitrite colorimetric assays, and iNOS phosphorylation levels in leukocyte membranes using Western blotting. Results Patients with HNSCC (n = 15) exhibited elevated baseline levels of VASH1, NO, and leukocyte-induced iNOS phosphorylation compared to non-cancer controls (n = 15). After tumor resection, plasma VASH1 levels were significantly downregulated (2233 ± 1464 pg·mL.sup.-1 vs. 2425 ± 1493 pg·mL.sup.-1, p = 0.0085), while plasma VASH2 levels remained unchanged in HNSCC patients. Similarly, VASH1 levels in leukocytes were reduced after surgery (0.85 ± 0.04 fold, p = 0.0068), while VASH2 levels did not change significantly. NO levels in plasma decreased significantly following surgery (0.29 ± 0.09 fold, p = 0.0001). Conversely, iNOS phosphorylation levels in leukocytes increased after surgery (1.52 ± 0.10 folds, p = 0.0024). The 3-year overall survival rates were 85.7% in patients with lower change folds of VASH1 in leukocytes, compared to 100.0% in those with higher change folds. Conclusions This study demonstrated that dynamic changes in VASH and NO signaling following tumor resection could serve as a potential indicator of tumor angiogenesis. Our findings suggest that the overall activity of the VASH pathway in leukocytes was reduced after tumor removal, highlighting the potential of leukocyte physiology as a novel biomarker for cancer surveillance and control. Keywords: Angiogenesis, Biomarker, Head and neck cancer, Nitric oxide, Vasohibin |
ArticleNumber | 221 |
Audience | Academic |
Author | Wu, Cheng-Hsien Lin, Tso-Chou Tai, Shyh-Kuan Lu, Chih-Cherng Tai, Ying-Hsuan Ho, Shung-Tai Chu, You-Hsiang Wu, Hsiang-Ling |
Author_xml | – sequence: 1 givenname: Ying-Hsuan surname: Tai fullname: Tai, Ying-Hsuan – sequence: 2 givenname: Hsiang-Ling surname: Wu fullname: Wu, Hsiang-Ling – sequence: 3 givenname: You-Hsiang surname: Chu fullname: Chu, You-Hsiang – sequence: 4 givenname: Cheng-Hsien surname: Wu fullname: Wu, Cheng-Hsien – sequence: 5 givenname: Shyh-Kuan surname: Tai fullname: Tai, Shyh-Kuan – sequence: 6 givenname: Tso-Chou surname: Lin fullname: Lin, Tso-Chou – sequence: 7 givenname: Shung-Tai surname: Ho fullname: Ho, Shung-Tai – sequence: 8 givenname: Chih-Cherng surname: Lu fullname: Lu, Chih-Cherng |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40483461$$D View this record in MEDLINE/PubMed |
BookMark | eNptkstq3TAQhk1JaZLTvkAXRVAo3TjVxZLsVQlJL4FAN-1ajGXZR6ksJZKdNIu8e-U4DedA0ULD6Jsfzcx_XBz44E1RvCX4hJBafEqENlyWmPISs5qzsn5RHJFKylLWpDnYiQ-L45SuMKaMcfaqOKxwVbNKkKPi4fzew2g10lvwg0nIenQLKWxtmyPwHfJ2ivk9_LGdQckOHpz1A-qDc-FuidIcB6vBoWiS0ZMNHoUebQ10a73Rv1G6mWEMc0LaOIc0RG19GOF18bIHl8ybp3tT_Pr65efZ9_Lyx7eLs9PLUnOKp5IIgUXTsI5TLgyrGG2x0C0hbctkBz3XDdRMN9IQpiUXvCUVlZJzLohom5ZtiotVtwtwpa6jHSHeqwBWPSZCHBTEyWpnFDa8o7LDBEtTNSCANdAabqSgugKGs9bnVet6bkfTaeOnCG5PdP_F260awq0ilFSVzAvYFB-fFGK4mU2a1GjTMhjwJs9IMZobbgSuZUbfr-gA-W_W9yFL6gVXp3XFMKeyXgRP_kPl05m82mya3ub8XsGHnYK8KjdtU3Dzsry0D77bbfa5y38GygBdAR1DStH0zwjBanGpWl2qskvVo0tVzf4CytzYzQ |
Cites_doi | 10.3892/or.2017.5746 10.1007/s12032-012-0212-1 10.4103/jcrt.jcrt_281_21 10.1200/JCO.2001.19.4.1207 10.1186/s12957-020-01991-9 10.1007/s10495-023-01832-6 10.1111/cas.14041 10.1016/j.oraloncology.2020.104977 10.1007/s12032-011-0106-7 10.1016/j.heliyon.2024.e30877 10.1111/j.1349-7006.2009.01483.x 10.1136/jclinpath-2013-201444 10.1038/nrc.2017.51 10.1016/j.oraloncology.2008.03.009 10.32471/exp-oncology.2312-8852.vol-41-no-3.13515 10.3390/ijms21249393 10.1177/01455613221078184 10.1158/1541-7786.MCR-12-0098-T 10.1111/j.1349-7006.2009.01388.x 10.1016/j.critrevonc.2022.103805 10.1038/bjc.2013.169 10.15761/GIMCI.1000132 10.1016/j.niox.2022.07.006 10.1016/j.canlet.2016.11.016 10.1620/tjem.243.107 10.1186/s12964-014-0062-x 10.3892/etm.2017.4969 10.1186/1476-4598-13-99 10.2353/ajpath.2009.080788 10.1111/micc.12608 10.1038/sj.cr.7290133 10.1182/blood.V94.11.3717 10.21873/anticanres.11437 10.1007/s11912-019-0799-x 10.1007/s00595-020-02040-4 10.1177/0022034518756297 10.1172/JCI200421152 10.1080/15384047.2017.1373217 |
ContentType | Journal Article |
Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
DOI | 10.1186/s12957-025-03853-8 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1477-7819 |
EndPage | 11 |
ExternalDocumentID | oai_doaj_org_article_0e5d27d0107e49a6a39abe5e762c4a30 PMC12144735 A843052785 40483461 10_1186_s12957_025_03853_8 |
Genre | Journal Article |
GeographicLocations | Taiwan |
GeographicLocations_xml | – name: Taiwan |
GrantInformation_xml | – fundername: Taipei Veterans General Hospital grantid: V110C-086 |
GroupedDBID | --- 0R~ 29R 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK IAO IHR IHW INH INR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ TR2 TUS UKHRP W2D WOQ WOW XSB ~8M CGR CUY CVF ECM EIF NPM PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
ID | FETCH-LOGICAL-c520t-16606993d5256e3432b06cb11bb37daf5c9a83c97e13c7565b14277555616b9b3 |
IEDL.DBID | DOA |
ISSN | 1477-7819 |
IngestDate | Wed Aug 27 01:25:20 EDT 2025 Thu Aug 21 18:25:21 EDT 2025 Fri Jul 11 17:13:15 EDT 2025 Thu Jun 19 01:37:35 EDT 2025 Tue Jun 17 03:40:44 EDT 2025 Tue Jun 17 02:10:56 EDT 2025 Thu Jun 12 01:53:13 EDT 2025 Thu Jul 03 08:14:32 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Angiogenesis Head and neck cancer Biomarker Nitric oxide Vasohibin |
Language | English |
License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c520t-16606993d5256e3432b06cb11bb37daf5c9a83c97e13c7565b14277555616b9b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/0e5d27d0107e49a6a39abe5e762c4a30 |
PMID | 40483461 |
PQID | 3216696087 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0e5d27d0107e49a6a39abe5e762c4a30 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12144735 proquest_miscellaneous_3216696087 gale_infotracmisc_A843052785 gale_infotracacademiconefile_A843052785 gale_healthsolutions_A843052785 pubmed_primary_40483461 crossref_primary_10_1186_s12957_025_03853_8 |
PublicationCentury | 2000 |
PublicationDate | 2025-06-07 |
PublicationDateYYYYMMDD | 2025-06-07 |
PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-07 day: 07 |
PublicationDecade | 2020 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | World journal of surgical oncology |
PublicationTitleAlternate | World J Surg Oncol |
PublicationYear | 2025 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | Z Shen (3853_CR11) 2012; 29 YH Tai (3853_CR23) 2020; 27 D Li (3853_CR29) 2010; 101 H Hara (3853_CR35) 2020; 50 M De Palma (3853_CR1) 2017; 17 P Salven (3853_CR41) 1999; 5 X Xue (3853_CR7) 2014; 12 Y Takahashi (3853_CR8) 2012; 10 G Zhao (3853_CR3) 2017; 38 A Aguayo (3853_CR40) 1999; 94 Q Wang (3853_CR15) 2012; 29 LB Schmitd (3853_CR20) 2018; 97 AW Girotti (3853_CR9) 2022; 179 M Vakkala (3853_CR17) 2000; 6 HB Jones (3853_CR19) 2009; 45 E Kopczyńska (3853_CR25) 2012; 2012 S Dios-Barbeito (3853_CR10) 2022; 128 FH Khan (3853_CR38) 2020; 21 M Zhang (3853_CR32) 2024; 10 S Kitahara (3853_CR6) 2014; 13 T Kosaka (3853_CR26) 2013; 108 C Torii (3853_CR12) 2017; 37 N Kanomata (3853_CR14) 2013; 66 B Zhang (3853_CR27) 2017; 14 S Liu (3853_CR28) 2022; 18 DK Zanoni (3853_CR21) 2019; 21 M Tu (3853_CR34) 2017; 388 R Sano (3853_CR13) 2017; 243 W Xu (3853_CR36) 2002; 12 K Watanabe (3853_CR2) 2004; 114 AM Elbehi (3853_CR30) 2020; 109 RT Poon (3853_CR39) 2001; 19 HL Wu (3853_CR18) 2020; 18 T Hosaka (3853_CR4) 2009; 175 VV Holotiuk (3853_CR37) 2019; 41 K Tamaki (3853_CR16) 2010; 101 Y Suzuki (3853_CR22) 2016; 1 R Iida-Norita (3853_CR5) 2019; 110 Z Xu (3853_CR31) 2023; 28 H Du (3853_CR24) 2017; 18 J Liu (3853_CR33) 2024; 103 |
References_xml | – volume: 38 start-page: 1021 year: 2017 ident: 3853_CR3 publication-title: Oncol Rep doi: 10.3892/or.2017.5746 – volume: 29 start-page: 2718 year: 2012 ident: 3853_CR11 publication-title: Med Oncol doi: 10.1007/s12032-012-0212-1 – volume: 18 start-page: 567 year: 2022 ident: 3853_CR28 publication-title: J Cancer Res Ther doi: 10.4103/jcrt.jcrt_281_21 – volume: 19 start-page: 1207 year: 2001 ident: 3853_CR39 publication-title: J Clin Oncol doi: 10.1200/JCO.2001.19.4.1207 – volume: 18 start-page: 209 year: 2020 ident: 3853_CR18 publication-title: World J Surg Oncol doi: 10.1186/s12957-020-01991-9 – volume: 28 start-page: 860 year: 2023 ident: 3853_CR31 publication-title: Apoptosis doi: 10.1007/s10495-023-01832-6 – volume: 110 start-page: 2296 year: 2019 ident: 3853_CR5 publication-title: Cancer Sci doi: 10.1111/cas.14041 – volume: 109 start-page: 104977 year: 2020 ident: 3853_CR30 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2020.104977 – volume: 2012 start-page: 638352 year: 2012 ident: 3853_CR25 publication-title: ISRN Oncol – volume: 29 start-page: 2727 year: 2012 ident: 3853_CR15 publication-title: Med Oncol doi: 10.1007/s12032-011-0106-7 – volume: 10 start-page: e30877 year: 2024 ident: 3853_CR32 publication-title: Heliyon doi: 10.1016/j.heliyon.2024.e30877 – volume: 101 start-page: 1051 year: 2010 ident: 3853_CR16 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01483.x – volume: 66 start-page: 613 year: 2013 ident: 3853_CR14 publication-title: J Clin Pathol doi: 10.1136/jclinpath-2013-201444 – volume: 17 start-page: 457 year: 2017 ident: 3853_CR1 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.51 – volume: 45 start-page: 10 year: 2009 ident: 3853_CR19 publication-title: Oral Oncol doi: 10.1016/j.oraloncology.2008.03.009 – volume: 41 start-page: 210 year: 2019 ident: 3853_CR37 publication-title: Exp Oncol doi: 10.32471/exp-oncology.2312-8852.vol-41-no-3.13515 – volume: 21 start-page: 9393 year: 2020 ident: 3853_CR38 publication-title: Int J Mol Sci doi: 10.3390/ijms21249393 – volume: 103 start-page: 650 issue: 10 year: 2024 ident: 3853_CR33 publication-title: Ear Nose Throat J doi: 10.1177/01455613221078184 – volume: 10 start-page: 1135 year: 2012 ident: 3853_CR8 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-12-0098-T – volume: 101 start-page: 448 year: 2010 ident: 3853_CR29 publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2009.01388.x – volume: 179 start-page: 103805 year: 2022 ident: 3853_CR9 publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2022.103805 – volume: 108 start-page: 2123 year: 2013 ident: 3853_CR26 publication-title: Br J Cancer doi: 10.1038/bjc.2013.169 – volume: 1 start-page: 1 year: 2016 ident: 3853_CR22 publication-title: Gen Intern Med Clin Innov doi: 10.15761/GIMCI.1000132 – volume: 128 start-page: 1 year: 2022 ident: 3853_CR10 publication-title: Nitric Oxide doi: 10.1016/j.niox.2022.07.006 – volume: 5 start-page: 487 year: 1999 ident: 3853_CR41 publication-title: Clin Cancer Res – volume: 388 start-page: 187 year: 2017 ident: 3853_CR34 publication-title: Cancer Lett doi: 10.1016/j.canlet.2016.11.016 – volume: 243 start-page: 107 year: 2017 ident: 3853_CR13 publication-title: Tohoku J Exp Med doi: 10.1620/tjem.243.107 – volume: 12 start-page: 62 year: 2014 ident: 3853_CR7 publication-title: Cell Commun Signal doi: 10.1186/s12964-014-0062-x – volume: 14 start-page: 3477 year: 2017 ident: 3853_CR27 publication-title: Exp Ther Med doi: 10.3892/etm.2017.4969 – volume: 13 start-page: 99 year: 2014 ident: 3853_CR6 publication-title: Mol Cancer doi: 10.1186/1476-4598-13-99 – volume: 175 start-page: 430 year: 2009 ident: 3853_CR4 publication-title: Am J Pathol doi: 10.2353/ajpath.2009.080788 – volume: 27 start-page: e12608 year: 2020 ident: 3853_CR23 publication-title: Microcirculation doi: 10.1111/micc.12608 – volume: 6 start-page: 2408 year: 2000 ident: 3853_CR17 publication-title: Clin Cancer Res – volume: 12 start-page: 311 year: 2002 ident: 3853_CR36 publication-title: Cell Res doi: 10.1038/sj.cr.7290133 – volume: 94 start-page: 3717 year: 1999 ident: 3853_CR40 publication-title: Blood doi: 10.1182/blood.V94.11.3717 – volume: 37 start-page: 1219 year: 2017 ident: 3853_CR12 publication-title: Anticancer Res doi: 10.21873/anticanres.11437 – volume: 21 start-page: 52 year: 2019 ident: 3853_CR21 publication-title: Curr Oncol Rep. doi: 10.1007/s11912-019-0799-x – volume: 50 start-page: 1530 year: 2020 ident: 3853_CR35 publication-title: Surg Today doi: 10.1007/s00595-020-02040-4 – volume: 97 start-page: 742 year: 2018 ident: 3853_CR20 publication-title: J Dent Res doi: 10.1177/0022034518756297 – volume: 114 start-page: 898 year: 2004 ident: 3853_CR2 publication-title: J Clin Invest doi: 10.1172/JCI200421152 – volume: 18 start-page: 827 year: 2017 ident: 3853_CR24 publication-title: Cancer Biol Ther doi: 10.1080/15384047.2017.1373217 |
SSID | ssj0023353 |
Score | 2.3794458 |
Snippet | Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible nitric oxide... Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and inducible... Abstract Background Angiogenesis is essential for tumor growth and metastasis, with various molecules, including vasohibin (VASH), nitric oxide (NO), and... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 221 |
SubjectTerms | Adult Aged Angiogenesis Angiogenic Proteins Biomarker Biomarkers, Tumor - blood Biomarkers, Tumor - metabolism Care and treatment Case-Control Studies Cell Cycle Proteins - blood Cell Cycle Proteins - metabolism Cellular signal transduction Female Follow-Up Studies Head and neck cancer Head and Neck Neoplasms - blood Head and Neck Neoplasms - metabolism Head and Neck Neoplasms - pathology Head and Neck Neoplasms - surgery Health aspects Humans Leukocytes - metabolism Male Middle Aged Neovascularization Neovascularization, Pathologic - metabolism Neovascularization, Pathologic - pathology Nitric oxide Nitric Oxide - blood Nitric Oxide - metabolism Nitric Oxide Synthase Type II - blood Nitric Oxide Synthase Type II - metabolism Phosphorylation Prognosis Prospective Studies Proteases Signal Transduction Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - blood Squamous Cell Carcinoma of Head and Neck - metabolism Squamous Cell Carcinoma of Head and Neck - pathology Squamous Cell Carcinoma of Head and Neck - surgery Vasohibin |
Title | Dynamic changes in vasohibin and nitric oxide signaling following surgical resection of head and neck squamous cell carcinoma |
URI | https://www.ncbi.nlm.nih.gov/pubmed/40483461 https://www.proquest.com/docview/3216696087 https://pubmed.ncbi.nlm.nih.gov/PMC12144735 https://doaj.org/article/0e5d27d0107e49a6a39abe5e762c4a30 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-6gnhZ_La6jhEED1K2bZqPHnd0l0XYRRYXBi8hX2UHsXW3M-rF_933ks4wxYMXL6U0aWnyvpO83yPkjeO-YrIIuWCS57UQNgc7A1FKUZemUF76uHt-di5OL-uPC77YKfWFZ8ISPHCauMMiwNekh7BBhroxwrDG2MADCLGrDYvROti8TTA1hlqMcbZJkVHicACrxmWOpVtxJ4zlamKGIlr_3zp5xyhND0zuWKCT-2R_dB3pUfrlB-RW6B6Su2fj5vgj8vtDqi5PUzLvQJcd_WGG_moJ0S81nacgvqD2aP9r6QPFkxsGk9FpC7zQ_8S7YX0TNSHFpKSY8UD7loK-9un94L7S4XptcL2A4po_dViLqOu_mcfk8uT48_vTfKyukDteFau8FBC7gHfiOXg9AfNLbSGcLUtrmfSm5a4xirlGhpI5CX4fLhdJybGeprCNZU_IXtd34RmhHmH-msoHqULtTa1aH1oL5rcMoECakJF3m8nW3xOIho7BhxI6kUYDaXQkjVYZmSM9tj0RADs-ALbQI1vof7FFRl4hNXXKJt2KsT5SiHFWScUz8jb2QEEGojoz5iPAkBASa9LzYNITBNBNml9vOEZjE55a6wLQQbMKJhlCRCUz8jRx0HZUNWL516LMiJrw1mTY05ZueRXxv0uEuZOMP_8fE_WC3KuiXIi8kAdkb3WzDi_Bz1rZGbktF3JG7syPzz9dzKKAwfVi_uUPj4goZQ |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dynamic+changes+in+vasohibin+and+nitric+oxide+signaling+following+surgical+resection+of+head+and+neck+squamous+cell+carcinoma&rft.jtitle=World+journal+of+surgical+oncology&rft.au=Tai%2C+Ying-Hsuan&rft.au=Wu%2C+Hsiang-Ling&rft.au=Chu%2C+You-Hsiang&rft.au=Wu%2C+Cheng-Hsien&rft.date=2025-06-07&rft.issn=1477-7819&rft.eissn=1477-7819&rft.volume=23&rft.issue=1&rft_id=info:doi/10.1186%2Fs12957-025-03853-8&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12957_025_03853_8 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-7819&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-7819&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-7819&client=summon |